139 related articles for article (PubMed ID: 12393585)
1. Oral anticoagulation reduces activated protein C less than protein C and other vitamin K-dependent clotting factors.
Simmelink MJ; de Groot PG; Derksen RH; Fernandez JA; Griffin JH
Blood; 2002 Dec; 100(12):4232-3. PubMed ID: 12393585
[TBL] [Abstract][Full Text] [Related]
2. Correlation between different intensities of anti-vitamin K treatment and coagulation parameters.
Jerkeman A; Astermark J; Hedner U; Lethagen S; Olsson CG; Berntorp E
Thromb Res; 2000 Jun; 98(6):467-71. PubMed ID: 10899345
[TBL] [Abstract][Full Text] [Related]
3. Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment.
D'Angelo A; Della Valle P; Crippa L; Fattorini A; Pattarini E; Viganò D'Angelo S
Haematologica; 2002 Oct; 87(10):1074-80. PubMed ID: 12368163
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors.
Zivelin A; Rao LV; Rapaport SI
J Clin Invest; 1993 Nov; 92(5):2131-40. PubMed ID: 8227329
[TBL] [Abstract][Full Text] [Related]
5. The mechanism of action of oral anticoagulants and its consequences for the practice of oral anticoagulation.
Hemker HC; Frank HL
Haemostasis; 1985; 15(4):263-70. PubMed ID: 4043827
[TBL] [Abstract][Full Text] [Related]
6. Plasma levels of protein C and vitamin K-dependent coagulation factors in patients on long-term oral anticoagulant therapy.
Takahashi H; Hanano M; Hayashi S; Arai Y; Yoshino N; Takakuwa E; Tatewaki W; Nagayama R; Takizawa S; Shibata A
Tohoku J Exp Med; 1986 Aug; 149(4):351-7. PubMed ID: 3775760
[TBL] [Abstract][Full Text] [Related]
7. Vitamin K2 (Menaquinone-7) supplementation does not affect vitamin K-dependent coagulation factors activity in healthy individuals.
Ren R; Liu J; Cheng G; Tan J
Medicine (Baltimore); 2021 Jun; 100(23):e26221. PubMed ID: 34115006
[TBL] [Abstract][Full Text] [Related]
8. Levels of vitamin K-dependent procoagulant and anticoagulant proteins in over-anticoagulated patients.
Penning-van Beest FJ; Gómez García EB; van der Meer FJ; van Meegen E; Rosendaal FR; Stricker BH
Blood Coagul Fibrinolysis; 2002 Dec; 13(8):733-9. PubMed ID: 12441913
[TBL] [Abstract][Full Text] [Related]
9. The inhibitor of prothrombin conversion in plasma of patients on oral anticoagulant treatment.
Bertina RM; Westhoek-Kuipers ME; Alderkamp GH
Thromb Haemost; 1981 Jun; 45(3):237-41. PubMed ID: 7281102
[TBL] [Abstract][Full Text] [Related]
10. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy.
Makris M; Greaves M; Phillips WS; Kitchen S; Rosendaal FR; Preston EF
Thromb Haemost; 1997 Mar; 77(3):477-80. PubMed ID: 9065997
[TBL] [Abstract][Full Text] [Related]
11. A critical evaluation of the prothrombin time for monitoring oral anticoagulant therapy.
Jackson CM; Esnouf MP; Lindahl TL
Pathophysiol Haemost Thromb; 2003; 33(1):43-51. PubMed ID: 12853712
[TBL] [Abstract][Full Text] [Related]
12. Management of Severe Bleeding in Patients Treated With Oral Anticoagulants: Proceedings Monograph From the Emergency Medicine Cardiac Research and Education Group-International Multidisciplinary Severe Bleeding Consensus Panel October 20, 2018.
Gibler WB; Racadio JM; Hirsch AL; Roat TW
Crit Pathw Cardiol; 2019 Sep; 18(3):143-166. PubMed ID: 31348075
[TBL] [Abstract][Full Text] [Related]
13. Coagulation assay with improved specificity to factor V mutants insensitive to activated protein C.
Kraus M; Zander N; Fickenscher K
Thromb Res; 1995 Nov; 80(3):255-64. PubMed ID: 8578552
[TBL] [Abstract][Full Text] [Related]
14. Maternal prophylactic vitamin K treatment and response in cord plasma of coagulation factor (II, VII, X) activity.
Felding C; Jul E
Pediatr Hematol Oncol; 1988; 5(1):77-80. PubMed ID: 3152955
[No Abstract] [Full Text] [Related]
15. Warfarin withdrawal. Pharmacokinetic-pharmacodynamic considerations.
Palareti G; Legnani C
Clin Pharmacokinet; 1996 Apr; 30(4):300-13. PubMed ID: 8983860
[TBL] [Abstract][Full Text] [Related]
16. Race against the clock: overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage.
Le Roux P; Pollack CV; Milan M; Schaefer A
J Neurosurg; 2014 Aug; 121 Suppl():1-20. PubMed ID: 25081496
[TBL] [Abstract][Full Text] [Related]
17. Incoagulability of the blood in systemic lupus erythematosus. A case due to hypoprothrombinemia and a circulating anticoagulant.
Corrigan JJ; Patterson JH; May NE
Am J Dis Child; 1970 Apr; 119(4):365-9. PubMed ID: 5434598
[No Abstract] [Full Text] [Related]
18. Effect of warfarin on plasma concentrations of vitamin K dependent coagulation factors in patients with stable control and monitored compliance.
Kumar S; Haigh JR; Tate G; Boothby M; Joanes DN; Davies JA; Roberts BE; Feely MP
Br J Haematol; 1990 Jan; 74(1):82-5. PubMed ID: 2310700
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacology of oral anticoagulants].
Richter M; Markwardt F
Z Gesamte Inn Med; 1979 Jan; 34(1):8-17. PubMed ID: 433362
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of activated protein C anticoagulant activity by prothrombin.
Smirnov MD; Safa O; Esmon NL; Esmon CT
Blood; 1999 Dec; 94(11):3839-46. PubMed ID: 10572099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
